NOTE AB (publ) (STO:NOTE)
Sweden · Delayed Price · Currency is SEK 191.50
-0.20 (-0.10%)
Aug 1, 2025, 5:29 PM CET
Inozyme Pharma Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 3,817 | 3,901 | 4,243 | 3,687 | 2,643 | 1,874 | Upgrade |
Revenue Growth (YoY) | -8.71% | -8.07% | 15.08% | 39.49% | 41.07% | 6.44% | Upgrade |
Cost of Revenue | 3,304 | 3,382 | 3,730 | 3,214 | 2,290 | 1,649 | Upgrade |
Gross Profit | 513.47 | 519.47 | 513.79 | 473.17 | 353.65 | 224.69 | Upgrade |
Selling, General & Admin | 145 | 155 | 138.29 | 115.09 | 97.73 | 84.95 | Upgrade |
Other Operating Expenses | 2.4 | 2.4 | -6.92 | -2.36 | -7.27 | -0.33 | Upgrade |
Operating Expenses | 147.39 | 157.39 | 131.37 | 112.73 | 90.46 | 84.62 | Upgrade |
Operating Income | 366.08 | 362.08 | 382.42 | 360.44 | 263.19 | 140.07 | Upgrade |
Interest Expense | -31.15 | -39.15 | -37.47 | -15.68 | -6.39 | -4.95 | Upgrade |
Interest & Investment Income | 8.1 | 8.1 | 2.79 | 0.84 | 0.3 | 0.31 | Upgrade |
Currency Exchange Gain (Loss) | 11.16 | -6.85 | 12.6 | -27.8 | -15 | 13.3 | Upgrade |
Other Non Operating Income (Expenses) | -6.74 | -6.74 | -6.49 | -6.02 | -3.96 | -3.31 | Upgrade |
EBT Excluding Unusual Items | 347.44 | 317.44 | 353.85 | 311.77 | 238.14 | 145.42 | Upgrade |
Merger & Restructuring Charges | -25 | -7 | -3 | -1 | -2 | - | Upgrade |
Other Unusual Items | - | - | 39 | - | 0.6 | -2.9 | Upgrade |
Pretax Income | 322.44 | 310.44 | 389.85 | 310.77 | 236.74 | 142.52 | Upgrade |
Income Tax Expense | 65.42 | 62.42 | 69.89 | 56.53 | 42.68 | 26.86 | Upgrade |
Net Income | 257.03 | 248.03 | 319.96 | 254.24 | 194.06 | 115.66 | Upgrade |
Net Income to Common | 257.03 | 248.03 | 319.96 | 254.24 | 194.06 | 115.66 | Upgrade |
Net Income Growth | -10.74% | -22.48% | 25.85% | 31.01% | 67.79% | 25.35% | Upgrade |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 28 | Upgrade |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 | Upgrade |
Shares Change (YoY) | -1.42% | -0.56% | 0.04% | 0.38% | 1.11% | 2.06% | Upgrade |
EPS (Basic) | 9.00 | 8.61 | 11.04 | 8.79 | 6.79 | 4.08 | Upgrade |
EPS (Diluted) | 8.99 | 8.61 | 11.04 | 8.78 | 6.72 | 4.05 | Upgrade |
EPS Growth | -9.42% | -22.04% | 25.73% | 30.65% | 65.93% | 22.73% | Upgrade |
Free Cash Flow | 526.32 | 512.32 | 250.11 | 3.38 | -60.62 | 172.77 | Upgrade |
Free Cash Flow Per Share | 18.42 | 17.78 | 8.63 | 0.12 | -2.10 | 6.05 | Upgrade |
Dividend Per Share | 7.000 | 7.000 | - | - | - | - | Upgrade |
Gross Margin | 13.45% | 13.32% | 12.11% | 12.83% | 13.38% | 11.99% | Upgrade |
Operating Margin | 9.59% | 9.28% | 9.01% | 9.78% | 9.96% | 7.47% | Upgrade |
Profit Margin | 6.73% | 6.36% | 7.54% | 6.89% | 7.34% | 6.17% | Upgrade |
Free Cash Flow Margin | 13.79% | 13.13% | 5.89% | 0.09% | -2.29% | 9.22% | Upgrade |
EBITDA | 452.02 | 448.02 | 456.58 | 414.3 | 305.22 | 169.49 | Upgrade |
EBITDA Margin | 11.84% | 11.48% | 10.76% | 11.24% | 11.55% | 9.04% | Upgrade |
D&A For EBITDA | 85.94 | 85.94 | 74.17 | 53.86 | 42.03 | 29.42 | Upgrade |
EBIT | 366.08 | 362.08 | 382.42 | 360.44 | 263.19 | 140.07 | Upgrade |
EBIT Margin | 9.59% | 9.28% | 9.01% | 9.78% | 9.96% | 7.47% | Upgrade |
Effective Tax Rate | 20.29% | 20.11% | 17.93% | 18.19% | 18.03% | 18.85% | Upgrade |
Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.